Please ensure Javascript is enabled for purposes of website accessibility

Why Selecta Biosciences Stock Is Dropping Today

By Prosper Junior Bakiny - Apr 29, 2021 at 1:06PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The progress of one of the company's clinical programs is being delayed.

What happened?

On Thursday, Selecta Biosciences (SELB 1.53%) announced an update to its collaboration with Asklepios BioPharmaceutical, a partnership focused on the development of MMA-101 and ImmTOR as a combination treatment for methylmalonic acidemia (MMA). Investors were not pleased with some of the information Selecta Biosciences revealed, however. As a result, the company's shares are dropping sharply today. Selecta Biosciences' stock was down by 16.5% as of 12:50 p.m. EDT.

So what

Selecta Biosciences announced that moving forward, it will hold the exclusive rights to advance the development of MMA-101 and ImmTOR as a combination treatment for MMA. Previously, Selecta Biosciences shared these rights with Asklepios BioPharmaceutical, but the latter opted to give all the rights to Selecta.

The most likely reason why Selecta Biosciences' stock is plunging today is the announcement that due to a manufacturing issue, the company now expects the submission of its investigational new drug (IND) application for MMA-101 and ImmTOR to be delayed at least until the fourth quarter of 2021.

Doctor looking stressed with his hand on his forehead.

Image source: Getty Images.

Drugmakers have to submit an IND application before starting human clinical trials for a new investigational medicine. Selecta Biosciences had previously said that the combo treatment of MMA-101 and ImmTOR would "enter the clinic in the second quarter of 2021 with preliminary data expected by year-end."

Now what

Most of Selecta Biosciences' programs are still in their early stages, and the company doesn't have any products on the market. Any delay in the progress of one its clinical programs is likely to scare off some investors, which is what is happening today. At any rate, for investors focused on the long term, it seems way too early to consider purchasing shares of this healthcare stock


Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Selecta Biosciences, Inc. Stock Quote
Selecta Biosciences, Inc.
SELB
$1.33 (1.53%) $0.02

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
311%
 
S&P 500 Returns
110%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/01/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.